Priya Palta1, Gerardo Heiss2, A Richey Sharrett3, Kelley Pettee Gabriel4, Keenan Walker5, Kelly R Evenson2, David Knopman6, Thomas H Mosley7, Dean F Wong8,9,10, Rebecca F Gottesman3,5. 1. Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. 2. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Department of Epidemiology, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 7. Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. 8. Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 9. Department of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. 10. Washington University in St. Louis, School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, MO, USA.
Abstract
BACKGROUND: Physical activity (PA) may slow the development of dementia by reducing the accumulation of amyloid. OBJECTIVE: We tested the hypothesis that higher levels of leisure-time PA in mid- or late-life were associated with lower brain amyloid burden in late-life among 326 non-demented participants from the Atherosclerosis Risk in Communities Study of brain florbetapir positron emission tomography (ARIC-PET) ancillary. METHODS: Self-reported PA was quantified using a past-year recall, interviewer-administered questionnaire in mid-life (1987-1989, aged 45-64 years) and late-life (2011-2013, aged 67-89 years). Continuous PA estimates were classified as 1) any leisure-time PA participation (yes/no); 2) meeting the 2018 United States' PA guidelines (yes/no); and 3) per 1 standard deviation (SD) higher metabolic equivalent of task (MET) minutes per week (MET·min·wk-1). A brain magnetic resonance imaging scan with Florbetapir PET was performed in late-life. Adjusted odds ratios (OR) of elevated amyloid burden, defined as a global cortical standardized uptake value ratio (>1.2), compared to no elevated amyloid burden were estimated according to PA measures. RESULTS: Among the 326 participants (mean age: 76 years, 42% male, 41% Black), 52% had elevated brain amyloid burden. Mid-life leisure-time PA did not show a statistically significant lower odds of elevated late-life amyloid burden (OR = 0.71, 95% CI: 0.43-1.18). A 1 SD (970 MET. min. wk-1) higher PA level in mid-life was also not significantly associated withelevated amyloid burden (OR = 0.89, 95% CI: 0.69-1.15). Similar estimates were observed for meeting versus not meeting PA guidelines in both mid- and late-life. CONCLUSION: Self-reported higher mid- and late-life leisure-time PA were not significantly associated with lower amyloid burden. Data show a trend of an association, which is, however, imprecise, suggesting replication in larger studies.
BACKGROUND: Physical activity (PA) may slow the development of dementia by reducing the accumulation of amyloid. OBJECTIVE: We tested the hypothesis that higher levels of leisure-time PA in mid- or late-life were associated with lower brain amyloid burden in late-life among 326 non-demented participants from the Atherosclerosis Risk in Communities Study of brain florbetapir positron emission tomography (ARIC-PET) ancillary. METHODS: Self-reported PA was quantified using a past-year recall, interviewer-administered questionnaire in mid-life (1987-1989, aged 45-64 years) and late-life (2011-2013, aged 67-89 years). Continuous PA estimates were classified as 1) any leisure-time PA participation (yes/no); 2) meeting the 2018 United States' PA guidelines (yes/no); and 3) per 1 standard deviation (SD) higher metabolic equivalent of task (MET) minutes per week (MET·min·wk-1). A brain magnetic resonance imaging scan with Florbetapir PET was performed in late-life. Adjusted odds ratios (OR) of elevated amyloid burden, defined as a global cortical standardized uptake value ratio (>1.2), compared to no elevated amyloid burden were estimated according to PA measures. RESULTS: Among the 326 participants (mean age: 76 years, 42% male, 41% Black), 52% had elevated brain amyloid burden. Mid-life leisure-time PA did not show a statistically significant lower odds of elevated late-life amyloid burden (OR = 0.71, 95% CI: 0.43-1.18). A 1 SD (970 MET. min. wk-1) higher PA level in mid-life was also not significantly associated withelevated amyloid burden (OR = 0.89, 95% CI: 0.69-1.15). Similar estimates were observed for meeting versus not meeting PA guidelines in both mid- and late-life. CONCLUSION: Self-reported higher mid- and late-life leisure-time PA were not significantly associated with lower amyloid burden. Data show a trend of an association, which is, however, imprecise, suggesting replication in larger studies.
Authors: Keenan A Walker; B Gwen Windham; Melinda C Power; Ron C Hoogeveen; Aaron R Folsom; Christie M Ballantyne; David S Knopman; Elizabeth Selvin; Clifford R Jack; Rebecca F Gottesman Journal: Neurobiol Aging Date: 2018-04-04 Impact factor: 4.673
Authors: David S Knopman; Michael E Griswold; Seth T Lirette; Rebecca F Gottesman; Kejal Kantarci; A Richey Sharrett; Clifford R Jack; Jonathan Graff-Radford; Andrea L C Schneider; B Gwen Windham; Laura H Coker; Marilyn S Albert; Thomas H Mosley Journal: Stroke Date: 2015-01-06 Impact factor: 7.914
Authors: Edo Richard; Sandrine Andrieu; Alina Solomon; Francesca Mangialasche; Satu Ahtiluoto; Eric P Moll van Charante; Nicola Coley; Laura Fratiglioni; Anna Stigsdotter Neely; Bruno Vellas; Willem A van Gool; Miia Kivipelto Journal: J Neurol Sci Date: 2012-07-19 Impact factor: 3.181
Authors: B M Brown; J J Peiffer; K Taddei; J K Lui; S M Laws; V B Gupta; T Taddei; V K Ward; M A Rodrigues; S Burnham; S R Rainey-Smith; V L Villemagne; A Bush; K A Ellis; C L Masters; D Ames; S L Macaulay; C Szoeke; C C Rowe; R N Martins Journal: Mol Psychiatry Date: 2012-08-14 Impact factor: 15.992
Authors: Jennifer S Rabin; Hannah Klein; Dylan R Kirn; Aaron P Schultz; Hyun-Sik Yang; Olivia Hampton; Shu Jiang; Rachel F Buckley; Anand Viswanathan; Trey Hedden; Jeremy Pruzin; Wai-Ying Wendy Yau; Edmarie Guzmán-Vélez; Yakeel T Quiroz; Michael Properzi; Gad A Marshall; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: JAMA Neurol Date: 2019-10-01 Impact factor: 18.302
Authors: Rebecca F Gottesman; Andrea L C Schneider; Yun Zhou; Josef Coresh; Edward Green; Naresh Gupta; David S Knopman; Akiva Mintz; Arman Rahmim; A Richey Sharrett; Lynne E Wagenknecht; Dean F Wong; Thomas H Mosley Journal: JAMA Date: 2017-04-11 Impact factor: 56.272
Authors: Grace Fletcher; Aniqa B Alam; Linzi Li; Faye L Norby; Lin Y Chen; Elsayed Z Soliman; Alvaro Alonso Journal: BMC Cardiovasc Disord Date: 2022-04-26 Impact factor: 2.174